Private Equity Looking for Interns - Gilde Healthcare

Private Equity Looking for Interns

2. August 2017

Gilde Healthcare Services, a lower mid-market buy-out fund focused on Benelux and Germany, is looking for a student intern that is able to support the investment team with its activities.

Given the compact investment team, the intern will have the opportunity to take an integral role in a deal team. The intern will have the opportunity to engage in many parts of the investment process, with an emphasis on the deal origination phase. Strong analytical skills, an excellent track record and an entrepreneurial spirit are therefore required. We assume fluency in English and either Dutch or German. A previous internship in corporate finance, strategy consultancy or private equity is appreciated. You will work 3 (or more) months in the city of Utrecht as member of our investment team.

More information: More information on Gilde Healthcare: gildehealthcare.com More information on this position: Mr. T. Klein Robbenhaar, robbenhaar@gildehealthcare.com When interested, please send your resume and concise motivational email and we will be in contact with you.

 

 

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor...
10. September 2025

Gilde Healthcare ernennt Dr. Christian Stark zum Group CEO ihrer global operierenden Medizintechnikgruppe

Die Medizintechnikgruppe, zu der zwei Hersteller chirurgischer Instrumente aus der Region Tuttlingen gehören, Koscher & Würtz und Christian Diener, hat Dr. Christian Stark mit Wirkung zum 1. September 2025 zum Chief Executive Officer (CEO) berufen....
3. September 2025

Gilde Healthcare company SynOx Therapeutics Completes Enrollment in Registrational Trial Significantly Ahead of Timeline

DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced completion of patient enrolment...
5. August 2025